[Glucose effectiveness and components of the metabolic syndrome in recently diagnosed hypertensive patients].
BACKGROUND
Glucose effectiveness (SG) is a parameter that indicates the glucose ability to clearing itself from the plasma independently of insulin's action. Our purpose was to analyze the cluster characteristics associated with the metabolic syndrome in a group of non-obese, recent-onset hypertensives and to test if there was a correlation with SG and the effectiveness of glucose at basal insulin point (GEZI).


METHODS
We studied 36 patients with mild hypertension with normal basal glucose levels. We determined plasma lipid subfractions, apolipoproteins and urate levels. An intravenous glucose tolerance test (TTGI) and minimal model analysis according to Bergman was performed and SG, GEZI and insulin sensitivity (SI) were calculated.


RESULTS
Patients with lower SG and GEZI had higher levels of total triglycerides (Tg) (r = 0.42; p = 0.01 and r = 0.48; p = 0.002, respectively) and triglycerides bind to VLDL (Tg-VLDL) (r = 0.40; p < 0.01 and r = 0.49; p = 0.002, respectively). When the cluster of metabolic syndrome was analyzed, SG was inversely related to uric acid levels and to the waist-hip index. However, SI was only related to the uric acid levels (r = 0.38; p = 0.01).


CONCLUSIONS
In non-obese, recently diagnosed hypertensive patients, the SG parameter seems to be an early marker for the development of metabolic syndrome.
García Morillo
José Salvador
JS
Unidad de Hipertensión Arterial y Lípidos. Servicio de Medicina Interna. Hospitales Universitarios Virgen del Rocío. Sevilla. España. salvaymar@navegalia.com
García-Junco
Pablo Stiefel
PS
Miranda Guisado
María Luisa
ML
Vallejo Maroto
Ignacio
I
Pamies Andreu
Encarnación
E
Muñiz Grigalvo
Ovidio
O
Carneado de la Fuente
Joaquín
J
Villar Ortiz
José
J
D000328:Adult; D000368:Aged; D015243:Cholesterol, VLDL / Q000097:blood; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D018149:Glucose Intolerance / Q000378:metabolism; D005951:Glucose Tolerance Test / Q000379:methods; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D007275:Injections, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D049528:Insulin, Long-Acting; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D010641:Phenotype; D011863:Radioimmunoassay; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D015243:Cholesterol, VLDL; D007328:Insulin; D049528:Insulin, Long-Acting; D014280:Triglycerides; D014527:Uric Acid; D005947:Glucose